MPO
ENSG00000005381
Target class
Enzyme
Chromosome
17
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- MPO
- Gene name
- Myeloperoxidase
- Gene symbol
- MPO
- Protein name
- Myeloperoxidase (MPO) (EC 1.11.2.2) [Cleaved into: Myeloperoxidase; 89 kDa myeloperoxidase; 84 kDa myeloperoxidase; Myeloperoxidase light chain; Myeloperoxidase heavy chain]
- Gene biotype
- Protein coding
- Gene family
- Heme peroxidase family
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 12
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 21.28
- Tissue specificity (Gini)
- 0.732
- Tissue specificity (tau)
- 0.957
- KEGG gene identifiers
- hsa:4353
- Protein interaction confidence
- 0.822959
- Protein interaction partners
- 74
- R-HSA-6798695
- R-HSA-8941413
- End position
- 58280935
- Start position
- 58269855
- Chromosome
- 17
- Strand
- Reverse
- Lysosome.
- Vesicles
- Tissue specificity (tau)
- 0.956962
- Expression inequality (Gini)
- 0.731765
Expression in transcripts per million
- Whole Blood
- 21.28
- Spleen
- 13.19
- Lung
- 6.57
- Pituitary
- 2.56
- Minor Salivary Gland
- 2.06
Expression in transcripts per million
- Whole Blood21.28
- Spleen13.19
- Lung6.57
- Pituitary2.56
- Minor Salivary Gland2.06
- Brain - Frontal Cortex (BA9)1.75
- Brain - Cortex1.74
- Brain - Cerebellum1.29
- Brain - Anterior cingulate cortex (BA24)1.22
- Testis1.19
- Brain - Hypothalamus1.08
- Brain - Cerebellar Hemisphere1.07
- Brain - Putamen (basal ganglia)0.93
- Brain - Caudate (basal ganglia)0.88
- Brain - Substantia nigra0.87
- Brain - Nucleus accumbens (basal ganglia)0.82
- Brain - Hippocampus0.82
- Brain - Amygdala0.78
- Muscle - Skeletal0.7
- Artery - Aorta0.61
- Brain - Spinal cord (cervical c-1)0.6
- Thyroid0.49
- Breast - Mammary Tissue0.48
- Adipose - Visceral (Omentum)0.47
- Liver0.44
And 29 more, listed on the interactive page.
- GO:0006337
- GO:0006952
- GO:0006979
- GO:0034374
- GO:0042744
- GO:0043066
- GO:0070943
- GO:0070944
- GO:0070947
- GO:0140645
- GO:1904109
- GO:0005576
- GO:0005634
- GO:0005764
- GO:0030141
- GO:0035578
- GO:0042582
- GO:0045335
- GO:0070062
- GO:0097013
- GO:0140644
- GO:0003682
- GO:0004601
- GO:0005515
- GO:0008201
- GO:0031491
- GO:0140776
Related records
Trials (29)
- A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease
- A Study in Participants With Non-cirrhotic NASH With Fibrosis
- A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
- A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers
- A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831
- A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers
- A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole
- A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.
- A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects
- A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects
- A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model
- A Study To Test The Safety, Amount And Effects Of PF-06282999 In Healthy Overweight Adults And A Study To Test The Effects Of PF-06282999 On The Amount Of The Approved Drug, Midazolam, In Healthy Adults
- An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.
- AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients
- Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients
- Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)
- HEALEY ALS Platform Trial - Master Protocol
- HEALEY ALS Platform Trial - Regimen B Verdiperstat
- Investigating Safety, Tolerability and Pharmakinetics When Giving Single and Fractionated Doses of AZD3241 to Healthy Volunteers
- Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)
Drugs (3)
- Mitiperstat
- PF-06282999
- Verdiperstat Myeloperoxidase inhibitor